Edition:
United Kingdom

Axovant Sciences Ltd (AXON.OQ)

AXON.OQ on NASDAQ Stock Exchange Global Select Market

5.38USD
20 Nov 2017
Change (% chg)

$0.39 (+7.82%)
Prev Close
$4.99
Open
$5.00
Day's High
$5.39
Day's Low
$4.95
Volume
319,430
Avg. Vol
384,388
52-wk High
$27.93
52-wk Low
$4.60

Summary

Name Age Since Current Position

Marion McCourt

57 2017 President, Chief Operating Officer

David Hung

60 2017 Chief Executive Officer, Director

Gregory Weinhoff

46 2015 Chief Financial Officer

Vivek Ramaswamy

31 2017 Director, Chief Executive Officer - Roivant Sciences

Mark Altmeyer

56 President of Axovant Sciences GmbH and Chief Commercial Officer

Eric Floyd

2017 Senior Vice President - Regulatory Affairs

Ilise Lombardo

2015 Senior Vice President - Clinical Research

Thomas Templeman

2017 Senior Vice President - Pharmaceutical Operations and Quality Assurance

Mark Wadley

2017 Senior Vice President, US Business

Samina Bari

2017 Vice President - Corporate Communications

Shankar Ramaswamy

2015 Vice President - Global Medical Affairs

Stephen Mohr

57 2017 General Counsel

Kathryn Falberg

56 2017 Director

Patrick Machado

53 2017 Director

Berndt Modig

58 2015 Director

Ilan Oren

33 2015 Director

Atul Pande

62 2015 Director

Anthony Vernon

61 2017 Director

Biographies

Name Description

Marion McCourt

Ms. Marion McCourt serves as President, Chief Operating Officer of the Company. She has more than two decades of wide-ranging experience at some of the world’s most innovative biopharmaceutical companies. She has extensive experience leading commercial functions including medical affairs, business development, finance, human resources, legal, operations, payer-government, and sales and marketing. Before joining Axovant, she was Chief Operating Officer of Medivation, Inc. until its acquisition by Pfizer Inc. Earlier in her career, she held multiple roles at Amgen including Vice President in US Commercial Operations and Vice President and General Manager at Amgen, where she was responsible for the bone health and primary care business unit. She served in a number of roles of increasing responsibility during a 12-year career at AstraZeneca including ultimately as Chief Operating Officer for AstraZeneca US. She received a BS in biology from Lafayette College.

David Hung

Dr. David T. Hung, M.D. serves as Chief Executive Officer, Director of the Company. Dr. Hung has served as Chief Executive Officer of Axovant Sciences, Inc. and a member of the board since April 2017. Previously, he was a co-founder of Medivation, Inc., a biopharmaceutical company, and served as its President and Chief Executive Officer and a member of its board of directors until its acquisition by Pfizer Inc. Before that, Dr. Hung was employed by ProDuct Health, Inc., a privately held medical device company, as Chief Scientific Officer and then as President and Chief Executive Officer. He has also served as a consultant to Cytyc Corporation to assist with transitional matters related to its acquisition of ProDuct Health, Inc. and has served as a member of the board of directors of Opexa Therapeutics, Inc., a biopharmaceutical company. Dr. Hung received an MD from the University of California, San Francisco, School of Medicine, and an AB in biology from Harvard College.

Gregory Weinhoff

Dr. Gregory M. Weinhoff, M.D., serves as Chief Financial Officer of the company. Dr. Weinhoff has served as Chief Financial Officer of Axovant Sciences, Inc. since August 2015. He has more than 20 years of experience in healthcare finance and operations including as a venture capital investor, operating executive and board member with Audit Committee experience. Previously, he was a partner at CHL Medical Partners, where he focused on investments in start-up and early-stage companies across therapeutics, diagnostics, medical devices and healthcare services. He was the founding Chief Executive Officer of Amicus Therapeutics and was subsequently a member of the Audit Committee of the company’s board of directors. Earlier in his career, he was founding President of VaxInnate and President of Resolvyx. He also held positions in the healthcare groups at J.H. Whitney & Co. and Morgan Stanley & Co. He received an MD from Harvard Medical School, an MBA from Harvard Business School (Baker Scholar), and an AB in economics (magna cum laude) from Harvard College.

Vivek Ramaswamy

Mr. Vivek Ramaswamy serves as a Director of Axovant Sciences Ltd. and Chief Executive Officer - Roivant Sciences, parent company of Axovant Sciences Ltd. Mr. Vivek Ramaswamy is founder and Chief Executive Officer of Roivant Sciences, Inc., and the founder and former Chief Executive Officer of Axovant Sciences, Inc. Prior to founding Roivant, Mr. Ramaswamy was a well-known investor in the biotechnology sector. In 2007, he co-founded and served as President of Campus Venture Network, a technology company that was acquired in 2009. He currently serves as Chairman of the Board of Directors of Arbutus Biopharma Corporation and a member of the Board of Directors of Axovant Sciences Ltd., Myovant Sciences Ltd., and Roivant Sciences Ltd. He received an A.B. summa cum laude in biology from Harvard College and a J.D. from Yale Law School.

Mark Altmeyer

Mr. Mark Altmeyer is a President of Axovant Sciences GmbH and Chief Commercial Officer subsidiary of the company. He has served as the President and Chief Commercial Officer of Axovant Sciences, Inc. since March 2015. From February 2009 to December 2014, Mr. Altmeyer served as Chief Executive Officer and President of Otsuka America Pharmaceutical, Inc. Prior to his time at Otsuka, Mr. Altmeyer served in a number of executive leadership roles at Bristol-Myers Squibb, including Senior Vice President, Global Commercialization from 2006 to 2008 and Senior Vice President, Neuroscience Business Unit from 2002 to 2005 during the approval and launch of Abilify, a branded drug used to treat multiple psychiatric conditions, including schizophrenia, depression and bipolar disorder. Mr. Altmeyer currently serves as a director for Contact of Mercer County. Mr. Altmeyer received his B.A. from Middlebury College and his M.B.A. from Harvard Business School.

Eric Floyd

Dr. Eric Floyd, Ph.D., serves as Senior Vice President - Regulatory Affairs of the Company. Dr. Floyd has served as senior vice president, regulatory affairs, for Axovant Sciences, Inc. since June 2017. He has nearly 20 years of regulatory experience within the pharmaceutical industry. Most recently, he was president of compliance services and chief scientific officer at Dohmen Life Science Services, Inc. He was Senior Vice President, US Regulatory Affairs and Clinical Quality Compliance at Lundbeck Inc., Global Vice President of Regulatory Affairs at Hospira, Vice President of Worldwide Regulatory Affairs and Quality Assurance at Cephalon and VP and Global Head of Respiratory, Dermatology, and Tropical Medicines Drug Regulatory Affairs at Novartis and held senior leadership roles at Bristol Myers Squibb, Aventis and Merck Research Laboratories. Dr. Floyd received a Ph.D. from Meharry Medical College, Nashville, an MBA from St. Joseph’s University, Philadelphia, an MS from Tennessee State University, and a BS from the University of Illinois.

Ilise Lombardo

Dr. Ilise Lombardo, M.D., serves as Senior Vice President - Clinical Research of the Company. Dr. Lombardo has served as Senior Vice President, clinical research, at Axovant Sciences. Inc. since April 2015. She has 15 years of experience in the pharmaceutical industry leading clinical development and medical affairs programs across multiple therapeutic areas including neurological and psychiatric disorders. She has successfully managed clinical development, regulatory authority approval and post-marketing activities. She is a trained psychiatrist and previously worked in academic research and clinical practice. Previously, she was Vice President, Clinical Development and Medical Affairs, at FORUM Pharmaceuticals. Earlier in her career, she led multi-therapeutic groups and development teams at Pfizer Inc. Prior to entering the pharmaceutical industry, she was an Assistant Professor of Clinical Research at Columbia University College of Physicians and Surgeons and the New York State Psychiatric Institute. She received an MD from Yale University, an M.Phil. from the University of Cambridge, and an AB from Brown University.

Thomas Templeman

Dr. Thomas Templeman, Ph.D., serves as Senior Vice President - Pharmaceutical Operations and Quality Assurance of the Company. Dr. Templeman has served as Senior Vice President, Pharmaceutical Operations and Quality Assurance, for Axovant Sciences, Inc. since June 2017. He has more than 25 years of experience across various aspects of pharmaceutical operations. He most recently served as Chief Operations Officer at Graybug Vision, and was at Medivation prior to that. He previously held positions of increasing responsibility at Hospira, Inc., Liquidia Technologies, and the Johnson & Johnson companies Centocor Biologics and Ortho Clinical Diagnostics. Dr. Templeman received a PhD from Dartmouth College and a BS from the University of Santa Clara.

Mark Wadley

Mr. Mark Wadley serves as Senior Vice President, US Business of the Company. Mr. Wadley has served as Senior Vice President, US Business, for Axovant Sciences, Inc. since May 2017. He has 24 years of commercial leadership experience across sales, marketing, payer access and commercial operations. Mr. Wadley most recently served as Senior Vice President of Sales at Guardant Health and previously was Vice President Oncology Sales, Organized Customers, and Payer at Medivation. He has also held various roles of increasing responsibility at Amgen, Wyeth BioPharma and Genetics Institute. Mr. Wadley holds a BS from Arizona State University.

Samina Bari

Ms. Samina Bari serves as Vice President - Corporate Communications of the Company. Ms. Bari has served as Vice President, Corporate Communications, for Axovant Sciences, Inc. since May 2017. She has more than 25 years of US and global communications experience in the healthcare and pharmaceutical industries. Most recently, she was Vice President of Corporate Communications at Medivation, and was Senior Vice President of Corporate Communications at Pharmacyclics prior to that. She has also held positions of increasing responsibility at Ikaria, Johnson & Johnson and Pfizer, in addition to having held senior-level positions at several of the world’s leading global communications firms. She began her career at a New York teaching hospital. Ms. Bari holds an MA and BA from New York University.

Shankar Ramaswamy

Dr. Shankar Ramaswamy, M.D., serves as Vice President - Global Medical Affairs of the Company. Dr. Ramaswamy is the vice president of global medical affairs for Axovant Sciences, Inc. and joined the company in March 2015. Dr. Ramaswamy was one of the earliest employees of Axovant and has served the company in multiple roles, including most recently as Vice President, Medical and Scientific Communications. He was also involved in the scientific evaluation of new assets for Axovant. Dr. Ramaswamy holds an AB in Economics from Harvard University and a MD from Brown University.

Stephen Mohr

Mr. Stephen F. Mohr serves as General Counsel of the Company. Mr. Mohr has served as General Counsel of Axovant Sciences, Inc. since June 2017. He has more than 25 years of experience in legal and compliance matters affecting the pharmaceutical industry. Before that, he served in a number of senior roles during a 12-year career at AstraZeneca, including US General Counsel and Deputy General Counsel, North America and Global Compliance Officer. Prior to that, he held roles of increasing responsibility during a 14-year career at Bristol-Myers Squibb, including Vice President and Senior Counsel, US Medicines. Earlier in his career, he specialized in litigation matters at Weiss Dawid Fross Zelnick & Lehrman, PC (now Fross Zelnick Lehrman & Zissu) and Rivkin Leff Sherman & Radler (now Rivkin Radler LLP). Mr. Mohr received a JD from the University of Virginia School of Law and a BA (magna cum laude) from Yale University.

Kathryn Falberg

Ms. Kathryn E. Falberg is a Director of the Company. Ms. Falberg has served as a member of the Board since April 2017. Previously, Ms. Falberg served as Executive Vice President and Chief Financial Officer of Jazz Pharmaceuticals plc, a multi-national specialty biopharmaceutical company, from March 2012 to March 2014 after serving as Senior Vice President and Chief Financial Officer since December 2009. Her responsibilities at Jazz Pharmaceuticals included strategy, corporate development, corporate communications, and information technology. From 2001 through 2009, Ms. Falberg served as a corporate director and audit committee chair for several companies. From 1995 to 2001, Ms. Falberg was with Amgen Inc., a biotechnology company, where she served as Senior Vice President, Finance and Strategy and Chief Financial Officer and prior to that as Vice President Chief Accounting Officer, and Vice President, Treasurer. Ms. Falberg also serves as a member of the board of directors for the public biopharmaceutical companies Aimmune Therapeutics, Inc., aTyr Pharma, Inc. and BioMarin Pharmaceutical Inc., and The Trade Desk, Inc., a publicly held technology company. Ms. Falberg also served on the board of directors of the public companies Medivation, Inc. and Halozyme Therapeutics, Inc. Ms. Falberg received an M.B.A. in Finance and B.A., in Economics from the University of California, Los Angeles and is a certified public accountant (inactive).

Patrick Machado

Mr. Patrick Machado, J.D., serves as a Director of the Company. Mr. Machado was a co-founder of Medivation, Inc., and served as its Chief Financial Officer from 2004 to 2014, as well as its Chief Business Officer from 2009 to 2014. He also served as a director of Medivation from April 2014 through September 2016. Mr. Machado currently serves on the boards of directors of several other biopharmaceutical companies, including Roivant Sciences, Ltd., the majority controlling shareholder of Axovant Sciences Ltd. Mr. Machado graduated from Santa Clara University summa cum laude with a Bachelor of Arts degree in German and a Bachelor of Science degree in Economics, and received his Juris Doctorate from Harvard Law School.

Berndt Modig

Mr. Berndt A.E. Modig is a Director of the company. Since March 2016, Mr. Modig has served as Chief Executive Officer of Pharvaris B.V. He served as Chief Financial Officer of Prosensa Holding N.V., a pharmaceutical company, from March 2010 until its acquisition by BioMarin Pharmaceutical Inc. in January 2015. From October 2003 to November 2008, Mr. Modig was Chief Financial Officer at Jerini AG, a pharmaceutical company, where he directed private financing rounds, its initial public offering in 2005, and its acquisition by Shire plc in 2008. Before that, Mr. Modig served as Chief Financial Officer at Surplex AG from 2001 to 2003 and as Finance Director Europe of U.S.-based Hayward Industrial Products Inc. from 1999 to 2001. In previous positions, Mr. Modig was a partner in the Brussels-based private equity firm Agra Industria from 1994 to 1999 and a Senior Manager in the Financial Services Industry Group of Price Waterhouse LLP in New York from 1991 to 1994. Mr. Modig currently serves as a director and member of the audit committee of Affimed N.V. (NASDAQ:AFMD) and as a director and the chair of the audit committee of Auris Medical Holding AG (NASDAQ:EARS), both publicly held pharmaceutical companies. He also serves on the supervisory board of Kiadis Pharma N.V., a public company whose shares are listed on the Euronext Amsterdam and Euronext Brussels stock exchanges. He also served as a director of Mobile Loyalty plc from 2012 to 2013. Mr. Modig received his bachelor’s degree in business administration, economics and German from the University of Lund, Sweden and his M.B.A. from INSEAD, Fontainebleau, France and is a Certified Public Accountant (inactive). We believe that Mr. Modig’s extensive international experience in finance and operations, private equity, and mergers and acquisitions qualifies him to serve on the Board.

Ilan Oren

Mr. Ilan Oren serves as Director of the company. Mr. Oren has served as a member of the Board since March 2015. Mr. Oren has served as Vice President, Business Development at Dexcel Pharma Technologies Ltd., an international pharmaceutical company involved in the development, manufacture and commercialization of pharmaceuticals, since September 2011. From 2007 to July 2011, he was employed by L.E.K. Consulting and advised clients in the life sciences sector on corporate strategy, mergers and acquisitions, licensing and drug commercialization projects. Mr. Oren currently serves as a director of Cynapsus Therapeutics Inc., a publicly traded specialty pharmaceutical company, and as a director of Roivant Sciences Ltd. Mr. Oren received his B.A. in Economics from Harvard College. We believe that Mr. Oren’s extensive leadership experience and knowledge of the life sciences industry qualifies him to serve on the Board.

Atul Pande

Dr. Atul Pande, M.D. serves as a Director of the Company. Dr. Pande has served as a member of the Board since March 2015. He serves as the Chief Medical Officer of PureTech Health. Since April 2014, Dr. Pande has served as President of Verity BioConsulting, a drug development consulting firm, and since December 2014 has served as Chief Medical Officer of Tal Medical, a clinical-stage medical device company. From 2007 to April 2014, Dr. Pande was Senior Vice President and Senior Advisor, Pharmaceutical R&D at GlaxoSmithKline, a pharmaceutical company. He has also held senior roles at Pfizer R&D, Parke-Davis/Warner-Lambert and Lilly Research Laboratories. Dr. Pande is also a non-executive board member of Autifony Therapeutics and of Karuna Pharmaceuticals. He also serves on the Scientific Advisory Boards of Cennerv Pharma and Centrexion Corporation. Dr. Pande completed his research fellowship training in psychiatry at the University of Michigan Medical School and his postgraduate specialty training and psychiatry residency program at Western University. We believe that Dr. Pande’s medical background and significant knowledge of the life sciences industry qualify him to serve on the Board.

Anthony Vernon

Mr. Anthony Vernon serves as Director of the Company. Mr. Vernon has served as a member of the Board since April 2017. Previously, Mr. Vernon served as senior advisor to Kraft Foods Group, Inc. from January 2015 through May 2015, and Chief Executive Officer for Kraft Foods Group, Inc. from October 2012 to December 2014. Mr. Vernon previously served as Executive Vice President and President at Kraft Foods of North America from 2009 to October 2012. From 2006 to 2009, Mr. Vernon was the Healthcare Industry Partner at Ripplewood Holdings, Inc., a private equity firm. Mr. Vernon previously led a number of Johnson & Johnson’s largest franchises during a 24-year career at Johnson & Johnson, a public company engaged in the research and development, manufacture, and sale of products in the healthcare field. From 2004 until 2005, Mr. Vernon was employed as Company Group Chairman of Depuy Inc., an orthopedics company, which is a subsidiary of Johnson & Johnson. From 2001 until 2004, Mr. Vernon served as President and Chief Executive Officer of Centocor, Inc., a biomedicines company, which is a division of Johnson & Johnson. He has also served as President of McNeil Consumer Products and Nutritionals, Worldwide President of The Johnson & Johnson-Merck Joint Venture, and as a member of Johnson & Johnson’s Group Operating Committees for Consumer Healthcare and Nutritionals, Biopharmaceuticals, and Medical Devices and Diagnostics. Mr. Vernon serves as a member of the board of directors of NovoCure Ltd., a medical device company, Intersect ENT, Inc., a medical device company, and The WhiteWave Foods Company, a consumer packaged food and beverage company, and formerly served as a director of Medivation, Inc. and Kraft Foods Group, Inc. Mr. Vernon received a B.A. from Lawrence University and an M.B.A. from the Northwestern University Kellogg Graduate School of Management.